Certain commonly prescribed sleeping pills are associated with a more than fourfold increased risk of death, even among those taking fewer than 18 doses a year, indicates research published in the online journal BMJ Open.
And these drugs are also associated with a significantly increased risk of cancer among those taking high doses, the study shows.
In 2010 between one in 20 and one in 10 adults took a sleeping pill in the US alone, say the authors, who tracked the survival of over 10,500 people with a range of underlying conditions, who were prescribed a range of sleeping pills for an average of 2.5 years between 2002 and 2007.
The drugs included benzodiazepines, such as temazepam; non-benzodiazepines, such as zolpidem, eszopiclone, and zaleplon; barbiturates; and sedative antihistamines.
The survival of these patients, whose average age was 54, was then compared with that of over 23,500 people matched for age, sex, lifestyle factors, and underlying health problems, but who had not been prescribed sleeping pills over the same period.
After taking account of factors likely to influence the results, including age, sex, weight, lifestyle, ethnicity and previously diagnosed cancer, the results pointed to a link between these drugs and an increased risk of death, even at relatively low doses.
Those prescribed up to 18 doses a year were more than 3.5 times as likely to die as those prescribed none, while those prescribed between 18 and 132 doses were more than four times as likely to do so.
And those taking the most doses (132+ a year) were more than five times as likely to die as those prescribed none, indicating that the level of risk rose in tandem with increasing doses, say the authors.
These associations were found in every age group, but were greatest among those aged 18 to 55.
Supplementary material posted alongside the paper shows that, although the overall numbers of deaths in each group were quite small, there were clear differences among them.
For example, there were 265 deaths among 4,336 people taking zolpidem, compared with 295 deaths among the 23,671 people who had not taken sedatives or sleeping pills.
Those taking the highest number of doses were also at greater risk of developing several types of cancer, and 35% more likely to be diagnosed with any type of cancer, overall. This association was not explained by pre-existing poor health, the data showed.
The authors point out that studies showing association don't necessarily prove cause and effect. But their findings back up previous research showing an increased risk of death among users of sleeping pills, they say.
Agreement is beginning to build that alternatives to sleeping pills for the treatment of insomnia may be warranted, they write.
And they ask if it isn't time to reconsider "whether even the short term use of hypnotics, as given qualified approval in National Institute for Health and Clinical Excellence [NICE] guidance, is sufficiently safe."
BMJ Open editor in chief, Dr Trish Groves, comments: "Although the authors have not been able to prove that sleeping pills cause premature death, their analyses have ruled out a wide range of other possible causative factors. So these findings raise important concerns and questions about the safety of sedatives and sleeping pills."
BMJ-British Medical Journal: http://www.bma.org
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Scientists find that antiretroviral treatment should be administered before HIV virus has weakened the immune system
Discovery of method for blocking enzyme that spreads cancer cells to bones is described as ‘important progress’ in prevention of secondary stage of disease
It seemed to make sense that the childhood Hib vaccine could cut leukemia risk by keeping the immune system in check. But proving there's cause and effect at work turns out to be a challenge.
A U.K. researcher says the environmental argument for eating bugs isn't working on its own. She says chefs and policymakers must "make insect dishes appeal as food, not just a way to save the planet."
Eating healthy is easier said than done. Same with buying healthy food. Research finds that putting in partitions in grocery carts can increase the likelihood shoppers buy healthy fruits and veggies.
Genetic study could provide hope for men with advanced forms of the disease with findings that could lead to personalised treatments
The agency that administers Obamacare in California moved to make expensive medicines more affordable in 2016. In most plans, patients will pay no more than $150 or $250 a month.
When former prisoners flock together, more land back in jail
Avian influenza is ravaging poultry flocks across the Upper Midwest. The virus is "doing things we've never seen it do before," and understanding about transmission is very limited, a scientist says.
Youthful blood has once again shown its promise as an elixir of youth – this time helping to rejuvenate bones. But exactly how it does so is still to be unravelled